 approach treatment cytomegaloviru retin ganciclovir foscarnet ganciclovir nucleosid analogu foscarnet pyrophosph analogu cytomegaloviru cmv dna polymeras inhibit cmv replic plasma concentr achiev intraven administr agent similar plasma half-liv kidney foscarnet low solubl high degre ioniz physiolog pH dose volum drug initi induct regimen long-term mainten regimen patient immun defici syndrom aid cmv retin efficaci long-term mainten therapi median time progress similar drug major toxic ganciclovir myelosuppress dose-limit neutropenia thrombocytopenia aid patient major toxic foscarnet nephrotox dose-limit toxic patient effect foscarnet hypocalcemia seizur arrhythmia studi vitro addit synergist inhibitori effect cmv drug lower-dos combin regimen higher-dos altern regimen efficaci toxic drug